Nice one all on track guys. Love these comments,
Neuren remains on schedule to receive top-line results from the trial in the second half of March 2017 and soon thereafter intends to engage potential commercial partners regarding the remaining development and commercialization of trofinetide in the major markets.
Ann: Neuren completes Phase 2 trial in pediatric Rett syndrome, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.13 |
Change
-0.070(0.49%) |
Mkt cap ! $1.753B | |||
| Open | High | Low | Value | Volume |
| $14.23 | $14.71 | $14.03 | $3.609M | 253.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 1005 | $14.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.13 | 461 | 8 |
View Market Depth
| Last trade - 14.23pm 30/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |